Company Overview and News

161
Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

2018-06-15 seekingalpha
Wright Medical Group N.V. (WMGI) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF-BB) and a blend of Type I collagen and Beta tricalcium phosphate. The combination is used as a safe and effective alternative to autograft for use in hindfoot and ankle fusion in an easy to use flowable formulation.
SGEN REGN CUTR K RVVTF SCPH PULM AGN MRK CRBP CAH CLSD TCON RVV

208
Brief Mid-Year Update On 2018 Global Asset Allocation

2018-06-15 seekingalpha
This brief update is meant to be read along with a review of my extensive December 28, 2017 note for many more details.
VRTX REGN AMGN GILD BIIB RGORF CELG AEM GOLD RRS GOLD

123
AGTC Announces Expansion of Clinical and Regulatory Leadership Teams

2018-06-14 globenewswire
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott, M.D., Appointed as Vice President of Clinical Research and Medical Affairs
AGTC REGN BMYMP BMY

90
Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms

2018-06-11 seekingalpha
Scynexis (NASDAQ:SCYX) is a drug manufacturer focusing on infectious diseases and has $83.85M in market capitalization. The company’s lead candidate SCY-078 is on trial for treatment of multiple serious fungal infections. Some of these fungal infections like Acute Vulvovaginal Candidiasis, Invasive Candidiasis and Invasive Aspergillosis Combo are difficult to treat and can turn into life-threatening conditions.
REGN MYO GSK ZTS CLRB GSK CLRBZ PRPO CLRBW PTI SCYX

80
Biogen’s O’Neill Heads to Sarepta Therapeutics

2018-06-08 biospace
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
REGN ALXN NG IONS NGGTF SRPT NGG

64
The Bull Case for Regeneron Pharmaceuticals Inc Couldn't Be More Clear | InvestorPlace

2018-06-07 investorplace
After falling from $393 per share early this year to a recent low of $284 per share, analysts have begun pounding the table again for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).
BRK.A REGN JPM ZTS

86
Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta

2018-06-05 zacks
Mylan N.V (MYL - Free Report) and partner Biocon announced that the FDA has approved Fulphila, a biosimilar of Amgen’s (AMGN - Free Report) Neulasta.
EMN.WS REGN AMGN EMN MNTA SAM

103
RPT-U.S. FDA wants to shorten new drug monopolies to cut costs

2018-06-04 reuters
CHICAGO, June 3 (Reuters) - In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.
PFZ REGN AMGN GILD 500680 PFE PFIZER

25
Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?

2018-06-04 zacks
A month has gone by since the last earnings report for Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . Shares have added about 2.7% in that time frame.
REGN WLK AVP

102
U.S. FDA wants to shorten new drug monopolies to cut costs

2018-06-03 reuters
CHICAGO (Reuters) - In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.
PFZ REGN AMGN GILD 500680 PFE PFIZER

102
FDA wants to shorten new drug monopolies to cut costs

2018-06-03 channelnewsasia
In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.
PFZ REGN AMGN GILD 500680 PFE PFIZER

13
The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It

2018-06-01 marketrealist
Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying. Here’s a breakdown of just how well the economy is doing:
REGN MLM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to REGN / Regeneron Pharmaceuticals, Inc. on message board site Silicon Investor.

2026 TeoTwawKi ... 2032 Darkest Interregnum Regeneron Pharmaceuticals
REGN
CUSIP: 75886F107